Monitoring disease activity in MS using serum neurofilament light protein
Determination of Neurofilament light in blood may improve the assessment of patients and should be considered as part of No Evidence of Disease Activity. In this MEDtalk Jan Lycke talks about that Neurofilament light (NFL) has the potential to become the first soluble biomarker to monitor disease activity and treatment response in clinical practice of MS.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen